NEO212 是一种口服有效、可透过血脑屏障的 Temozolomide (TMZ) (MS-Y83040)-Perillyl Alcohol (POH) (MS-C73762) 共轭化合物,具有强效抗癌活性,它通过耗竭 MGMT 克服经典 TMZ 耐药与 DNA 烷基化,通过抑制 FAK/Src 信号通路减少 MMP2 和 MMP9 的生成、诱导间质-上皮转化并抑制胶质瘤干细胞的迁移、侵袭及肿瘤进展,同时破坏自噬通量 (autophagy flux) 以增强线粒体凋亡 (apoptosis),并诱导急性髓系白血病 (AML) 细胞向巨噬细胞分化与增殖停滞。
产品编号: MS-K86095 CAS No.: 1361198-79-9 分子式: C17H20N6O4 分子量: 372.39
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

NEO212 是一种口服有效、可透过血脑屏障的 Temozolomide (TMZ) (MS-Y83040)-Perillyl Alcohol (POH) (MS-C73762) 共轭化合物,具有强效抗癌活性,它通过耗竭 MGMT 克服经典 TMZ 耐药与 DNA 烷基化,通过抑制 FAK/Src 信号通路减少 MMP2 和 MMP9 的生成、诱导间质-上皮转化并抑制胶质瘤干细胞的迁移、侵袭及肿瘤进展,同时破坏自噬通量 (autophagy flux) 以增强线粒体凋亡 (apoptosis),并诱导急性髓系白血病 (AML) 细胞向巨噬细胞分化与增殖停滞。

生物实验数据

生物活性 NEO212 is an orally effective, blood-brain barrier-permeable Temozolomide (TMZ) (MS-Y83040)-Perillyl Alcohol (POH) (MS-C73762) conjugate with potent anticancer activity that overcomes classical TMZ resistance and DNA alkylation by depleting MGMT, inhibits the FAK/Src signaling pathway to reduce MMP2 and MMP9 production, induce mesenchymal-to-epithelial transition, and suppress the migration, invasion, and tumor progression of glioma stem cells, and disrupts autophagy flux to enhance mitochondrial apoptosis (apoptosis) while inducing macrophage differentiation and proliferation arrest in acute myeloid leukemia (AML) cells.
体外研究
(In Vitro)

NEO212 (5-50 μM; 24 h) 可在非细胞毒性剂量下可逆性抑制间质型 USC02 胶质瘤干细胞的迁移,其迁移抑制活性在 24 h 后仍保持稳定,且与其短效的细胞毒性 DNA 烷化作用无关。
NEO212 (15 μM; 16 h) 可显著降低间质型 USC02 胶质瘤干细胞及新鲜分离的患者来源胶质瘤细胞的侵袭能力。
NEO212 (3-15 μM) 可降低间质型 USC02 和前神经型 USC04 胶质瘤干细胞中侵袭相关蛋白 MMP2 和 MMP9 的表达水平。
NEO212 (3-15 μM) 可选择性阻断间质型 USC02 和原神经型 USC04 胶质瘤干细胞中 FAK/Src 信号通路及其下游激酶的激活,其作用机制不同于 TMZ 的非特异性蛋白质合成抑制作用。
NEO212 (3-15 μM) 可通过调控关键 EMT 相关基因逆转间质型 USC02 胶质瘤干细胞的 EMT 表型,并促进神经元前体型 USC04 胶质瘤干细胞向上皮样特征转变。
NEO212 (25-300 μM; 48 h) 可呈剂量依赖性地抑制 A2780、SK-O-V3 和 OVCAR-3 人卵巢癌细胞的活力,且其效力强于 TMZ、POH 或二者的联合用药。
NEO212 (100 μM; 48 h) 可强效抑制 A2780、SK-O-V3 和 OVCAR-3 人卵巢癌细胞的集落形成,其效力优于 TMZ、POH 或二者联用。
NEO212 (100 μM; 48 h) 可诱导 A2780、SK-O-V3 和 OVCAR-3 人卵巢癌细胞发生 G2/M 期细胞周期阻滞。
NEO212 (100 μM; 48 h) 可在人卵巢癌细胞 A2780 和 SK-O-V3 中诱导强烈的 DNA 损伤,这一点可通过 ATM、CHEK1、CHEK2 和 H2AFX 的磷酸化水平升高得到证实。
NEO212 (100 μM; 48 h) 主要通过半胱天冬酶依赖的线粒体途径诱导 A2780、SK-O-V3 和 OVCAR-3 人卵巢癌细胞发生凋亡,同时存在少量半胱天冬酶非依赖的作用组分。
NEO212 (100 μM; 48 h) 可诱导 A2780 和 SK-O-V3 人卵巢癌细胞发生线粒体分裂及形态损伤,表现为线粒体长宽比降低、内部基质变形。
NEO212 (100 μM; 48 h) 可诱导人卵巢癌细胞 A2780 和 SK-O-V3 发生线粒体功能障碍,表现为线粒体跨膜电位显著降低。
NEO212 (100 μM; 48 h) 可诱导人卵巢癌细胞 A2780 和 SK-O-V3 中自噬体积累,但不会促进过度的自噬降解。
NEO212 (100 μM; 48 h) 通过损伤溶酶体功能并减少自噬体-溶酶体融合,阻断 A2780 和 SK-O-V3 人卵巢癌细胞中的自噬流。
NEO212 (100 μM; 48 h) 可通过上调 AKT 和 ERK 的磷酸化水平,抑制人卵巢癌细胞 A2780 和 SK-O-V3 中 TFEB 的核转位,进而导致溶酶体功能受损。
NEO212 (1-100 μM; 4-5 days) 可强效降低犬源 CLBL1 细胞、犬源 CLL1390 细胞、人源 HL60 细胞、人源 THP1 细胞、人源 Raji 细胞和人源 U937 细胞的活力,其 IC50 值范围为 1.7 至 42 μM;且与 O6BG 联合处理可增强其对 MGMT 高表达 CLL1390 细胞的细胞毒性。
NEO212 (1-70 μM; 3-7 days) 可诱导犬源 CLBL1 细胞、犬源 CLL1390 细胞、人源 HL60 细胞、人源 Raji 细胞和人源 U937 细胞发生细胞凋亡,且在耐 TMZ 的 CLL1390 细胞中仍具有活性。
NEO212 (0-100 μM; 5 days) 在体外可强效抑制人 AML 细胞系 U937、6D10、HL60、KG1 和 THP1 的活性,其 IC50 值范围为 ≤ 5 μM 至 50 μM,且在 MGMT 阳性 AML 细胞中的效果优于 TMZ。
NEO212 (50-100 μM; 16-32 h) 以时间和浓度依赖性方式下调人 THP1 和 HL60 急性髓系白血病 (AML) 细胞中的 MGMT 蛋白水平,而 TMZ 不会改变 MGMT 水平。
NEO212 (30 μM; 1-5 days) 可刺激人源阿糖胞苷耐药性 6D10 AML 细胞中巨噬细胞分化标记基因的表达。
NEO212 (10-100 μM; 3-5 days) 可在体外显著上调人 U937、6D10、THP1 和 HL60 AML 细胞中 CD11b mRNA 的水平,该效应无法由等摩尔浓度的 TMZ 与 POH 混合物模拟。
NEO212 (10-100 μM; 3-5 days) 可在体外上调人 U937、6D10、HL60 和 THP1 AML 细胞的细胞表面 CD11b 蛋白水平,该效应无法被 TMZ、POH 或它们的等摩尔混合物复制。

Cell Migration Assay

Cell Line: mesenchymal patient-derived glioma stem cells (USC02)
Concentration: 5, 15, 25 and 50 μM
Incubation Time: 24 h
Result: Showed dose-dependent impaired migration compared to vehicle-treated cells.
Caused no significant difference in viable cell count compared to vehicle controls after 24 h treatment.
Regained migratory ability after 24 h treatment followed by 48 h drug-free recovery, showing significantly larger wound area than cells treated continuously for 72 h.

Cell Invasion Assay

Cell Line: mesenchymal patient-derived glioma stem cells (USC02), freshly derived patient glioma cells
Concentration: 15 μM
Incubation Time: 16 h
Result: Significantly decreased the invasion rate of USC02 cells, while TMZ and/or perillyl alcohol showed no significant effects.
Decreased invasion capacity in all five tested samples of freshly derived patient glioma cells, despite varying baseline invasion rates.

Cell Viability Assay

Cell Line: A2780, SK-O-V3, OVCAR-3 human ovarian cancer cell lines
Concentration: 25, 50, 100, 150, 200, 300 μM
Incubation Time: 48 h
Result: Inhibited cell viability in a dose-dependent manner across all three cell lines, with stronger inhibitory effects than its individual constituents (TMZ, POH) and their combination.

Cell Cycle Analysis

Cell Line: A2780, SK-O-V3, OVCAR-3 human ovarian cancer cell lines
Concentration: 100 μM
Incubation Time: 48 h
Result: Increased the population of cells in the G2/M phase and decreased the population in the G1 phase across all three cell lines, indicating G2/M arrest.

Western Blot Analysis

Cell Line: A2780, SK-O-V3 human ovarian cancer cell lines
Concentration: 100 μM
Incubation Time: 48 h
Result: Induced higher levels of phosphorylated ATM (Ser1981), phosphorylated CHEK1 (Ser345), phosphorylated CHEK2 (Thr68), and phosphorylated H2AFX (Ser139) compared to TMZ, POH, or their combination, indicating stronger DNA damage.

Apoptosis Analysis

Cell Line: A2780, SK-O-V3, OVCAR-3 human ovarian cancer cell lines
Concentration: 100 μM; 100 μM (with concurrent 20 μM Z-VAD-FMK or 10 μM Ac-LEHD-FMK)
Incubation Time: 48 h; 48 h
Result: Induced significantly higher levels of apoptotic and dead cells compared to TMZ, POH, or their combination in all three cell lines.
Both Z-VAD-FMK and Ac-LEHD-FMK significantly reduced NEO212-induced apoptosis, but did not completely block it.

Cell Cytotoxicity Assay

Cell Line: human acute myeloid leukemia (AML) cell lines U937, 6D10, HL60, KG1, THP1
Concentration: 0-10 μM (U937, 6D10); 0-100 μM (HL60, KG1, THP1)
Incubation Time: 5 days
Result: Potently inhibited viability of all tested AML cell lines, with IC50 values of ≤ 5 μM for U937, 6D10, HL60, and KG1 cells; THP1 cells had an IC50 around 50 μM.
Was far more potent than TMZ in MGMT-positive HL60, KG1, and THP1 cells, and equally potent as TMZ in MGMT-negative U937 and 6D10 cells.
Did not have its cytotoxic potency mimicked by an equimolar mix of TMZ and POH.

Western Blot Analysis

Cell Line: human AML cell lines THP1, HL60
Concentration: 50, 75, 100 μM (24 h incubation); 80 μM (16, 24, 32 h incubation); 60, 80 μM (24 h incubation)
Incubation Time: 16 h, 24 h, 32 h
Result: Caused striking down-regulation of MGMT protein levels in THP1 and HL60 cells, with the effect detectable as early as 16 h after treatment with 50 μM NEO212, and more pronounced in THP1 cells than HL60 cells.
Showed no effect on MGMT protein levels when compared to TMZ treatment at concentrations up to 200 μM.

Real Time qPCR

Cell Line: human AML cell lines U937, 6D10, THP1, HL60
Concentration: 10 μM (U937, 6D10); 50 μM (THP1); 75, 100 μM (HL60)
Incubation Time: 3, 5 days (U937, 6D10, THP1); 5 days (HL60)
Result: Caused significant induction of CD11b transcript in all tested AML cell lines, with increases observed across different concentrations and time points.
Did not have its CD11b expression induction mimicked by an equimolar mix of TMZ and POH, while the positive control TPA did.
体内研究
(In Vivo)

NEO212 (5-25 mg/kg;皮下注射;给药 5 天、停药 2 天循环给药共 35 天) 可显著延长胶质母细胞瘤原位小鼠模型的生存期、延缓肿瘤进展并减少胶质瘤干细胞侵袭。
NEO212 (25 mg/kg;每日一次;共 15 天) 在体内展现出强效的抗卵巢癌活性,可将肿瘤生长抑制至第 1 天的终末体积倍数约为 10,诱导肿瘤坏死与凋亡,且在 BALB/c 裸鼠中未表现出显著的全身毒性。
NEO212 (25 mg/kg;口服;每个周期连续 5 天每日 1 次;共 2 个周期) 可显著延长携带人源或犬源白血病/淋巴瘤异种移植物的小鼠的生存期,在两个模型中 200 天时的存活率达 100%,疗效优于 TMZ。
NEO212 (25 mg/kg;口服;每周期连续 5 天每日 1 次;共 3 个周期) 处理可使小鼠获得 > 300 天的 100% 存活率,对小鼠体内耐阿糖胞苷 (AraC) 的 AML 表现出明确的治愈活性。
NEO212 (25 mg/kg;口服;每个周期连续 5 天每日一次;共 2 个周期) 处理使小鼠获得了超过 300 天的 100%存活率,对 TMZ 耐药的 AML 表现出明确的治愈活性。
NEO212 (100-200 mg/kg;口服;每日 1 次;连续 5 天) 在大鼠中具有良好的耐受性,当给药剂量高达 200 mg/kg、连续给药 5 天时,未观察到严重骨髓抑制或死亡情况。

Animal Model: NOD/SCID (8-10 week old male; intracranial implantation of luciferase-labeled mesenchymal USC02 glioma stem cells)
Dosage: 5 mg/kg; 25 mg/kg
Administration: s.c.; 5 days on, 2 days off cycles for 35 days
Result: Prolonged mouse survival significantly.
Delayed tumor progression highly significantly.
Reduced invasion of human tumor cells into normal brain parenchyma, showing a clear distinct border between tumor and normal brain.
Animal Model: BALB/c nude (female, 4-6 weeks of age, subcutaneous inoculation of 5×106 SK-O-V3 cells)
Dosage: 25 mg/kg
Administration: daily; 15 days
Result: Reduced final fold tumor volume relative to day 1 to ~10, compared to ~40 in DMSO control.
Induced necrotic foci in tumors via H&E staining.
Increased cleaved caspase-3 staining, indicating enhanced apoptosis.
Showed no statistically significant difference in body weight compared to control.
Caused no morphological/histological changes in major organs (heart, liver, spleen, lung, kidney).
Animal Model: NOD-SCID or NSG-SGM3 (female, 6-8 weeks old, implanted with human or canine leukaemia/lymphoma cells)
Dosage: 25 mg/kg
Administration: p.o.; once daily for 5 consecutive days per cycle; two cycles total
Result: Prolonged survival significantly in all five tumour models.
Achieved 100% survival at 200 days in human HL60 leukaemia and canine CLL1390 leukaemia models.
Showed significantly prolonged survival compared to vehicle controls in human U937 leukaemia model.
Extended survival significantly longer than vehicle and TMZ-treated mice in human Raji lymphoma model.
Extended survival significantly longer than vehicle and TMZ-treated mice in canine CLBL1 lymphoma model.
Extended survival significantly longer than vehicle and TMZ-treated mice in canine CLL1390 leukaemia model.
Animal Model: NOD-SCID (female, 6-8 weeks old, injected intraperitoneally with 5×104 MGMT-negative, AraC-resistant 6D10 AML cells)
Dosage: 25 mg/kg
Administration: p.o.; once daily for 5 consecutive days per cycle; 3 total cycles
Result: Ensured 100% of treated mice survived > 300 days without signs of disease.
Rendered human AML cells undetectable in blood via sensitive Alu sequence PCR assay.
Animal Model: NOD-SCID (female, 6-8 weeks old, injected intraperitoneally with 5×104 MGMT-positive, TMZ-resistant HL60 AML cells)
Dosage: 25 mg/kg
Administration: p.o.; once daily for 5 consecutive days per cycle; 2 total cycles
Result: Ensured 100% of treated mice survived > 300 days without signs of disease.
Rendered human AML cells undetectable in blood via sensitive Alu sequence PCR assay.

化学信息

分子量 372.39
分子式 C17H20N6O4
CAS No. 1361198-79-9

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础